Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension

American Journal of Hypertension

Volumn 21, Issue 4, 2008, Pages 464-470

  Pierdomenico, Sante D ^a   Lapenna, Domenico ^a   Cuccurullo, Franco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PROGNOSIS; RECOVERY OF FUNCTION; RISK FACTORS;

EID: 41349100305     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.2     Document Type: Article

References (27)

1. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascualr morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178.
2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
3. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117:831-836.
4. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, Ambrosio G. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104:2039-2044.
5. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
6. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1095.
7. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricualr mass in essential hypertension. Circulation 1998; 97:48-54.
8. Cipriano C, Gosse P, Bemurat L, Mas D, Lemetayer P, N'Tela G, Clementy J. Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 2001; 14:524-529.
9. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002; 15:1021-1028.
10. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
11. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens 2006; 19:493-499.
12. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Salvetti A, Trimarco B; for the SAMPLE study group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95:1464-1470.
13. Verdecchia P, Reboldi G, Porcellati C, Schillaci G, Pede S, Bentivoglio M, Angeli F, Norgiolini S, Ambrosio G. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol 2002; 39:878-885.
14. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension. A meta-analysis. Am J Hypertens 2003; 16:895-899.
15. Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlof B. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens 2002; 20:1445-1450.
16. Pierdomenico SD, Lapenna D, Guglielmi MD, Antidormi T, Schiavone C, Cuccurullo F, Mezzetti A. Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1995; 26:801-807.
17. Sahn DJ, DeMaria A, Kisslo J, Weyman A; for the Committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
19. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25:1056-1062.
20. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure. N Engl J Med 1971; 285:1441-1446.
21. Altman DG. Practical Statistics for Medical Research. Chapman & Hall: London, 1991.
22. Devereux RB, Roman MJ. Hypertensive cardiac hypertrophy: pathophysiological and clinical characteristics. In Laragh JH, Brenner BM (eds), Hypertension: Pathophysiology, Diagnosis and Management, 2nd edn. Raven Press: New York, 1995, pp 409-424.
23. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol 1995; 25:83-90.
24. Devereux RB, Agabiti-Rosei E, Dahlof B, Gosse P, Hahn RT, Okin PM, Roman MJ. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens 1996; 14(Suppl):S95-S102.
25. Benjamin EJ, Levy D. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999; 317:168-175.
26. Gosse P, Dubourg O, Gueret P. Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study. J Hypertens 2003; 21:217-221.
27. Douglas PS, Khandheria B, Stainback RF, Weissman RJ, Brindis RG, Patel MR, Alpert JS, Fitzgerlad D, Heidenreich P, Martin ET, Messer JV, Miller AB, Picard MH, Raggi P, Reed KD, Rumsfeld JS, Steimle AE, Tonkovic R, Vijayaraghavan K, Yeon SB, Hendel RC, Peterson E, Wolk MJ, Allen JM. ACCF/ASE/ACEP/ASNC/SCAI/ SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol 2007; 50:187-204.